Larotrectinib (Vitrakvi,Larodx)

Larotrectinib is the world’s first highly selective neurotrophic tyrosine receptor kinase (TRK) inhibitor and a tissue-agnostic precision targeted antineoplastic agent.

25mg*60capsules
100mg*60capsules

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Larotrectinib Drug News

Larotrectinib(Vitrakvi)

Indications：Larotrectinib is the world’s first highly selective neurotrophic tyrosine receptor kinase ···

WhatsApp
Official Service

TRK Inhibitor Vitrakvi Demonstrates Favorable Efficacy in the Treatment of NTRK Fusion-Positive Soli

EMA CHMP Positive Review OpinionRecently, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a po···【More】
Update: 11 Mar,2026Source: BigbearViews: 200
Bayer Submits New Drug Application for Vitrakvi (larotrectinib) in Japan for TRK Fusion-Positive Sol

NDA Submission AnnouncementOn May 26, 2020, Bayer announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour ···【More】
Update: 11 Mar,2026Source: BigbearViews: 202
FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

FDA Approval AnnouncementNovember 26, 2018 -- The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib).Vit···【More】
Update: 11 Mar,2026Source: BigbearViews: 202
U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK

Approval AnnouncementWHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has grant···【More】
Update: 11 Mar,2026Source: BigbearViews: 214